Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice

Affiliations

Comment

Lindsey E Roeker et al. Br J Haematol. 2021 Jul.

. 2021 Jul;194(1):9-10.

doi: 10.1111/bjh.17472. Epub 2021 Jun 15.

¹ CLL Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available

Comment on

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
Eyre TA, Preston G, Kagdi H, Islam A, Nicholson T, Smith HW, Cursley AP, Ramroth H, Xing G, Gu L, Rajakumaraswamy N, Fegan C. Eyre TA, et al. Br J Haematol. 2021 Jul;194(1):69-77. doi: 10.1111/bjh.17475. Epub 2021 Jun 14. Br J Haematol. 2021. PMID: 34121184 Free PMC article.

1. Eyre TA, Preston G, Kagdi H, Islam A, Nicholson T, Smith HW, et al. A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel). Br J Haematol. 2021;194:69-77.
1. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.
1. Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446-55.
1. Bange E, Nabhan C, Brander DM, Lamanna N, Ujjani CS, Howlett C, et al. Real-world evidence for durable treatment responses after toxicity related discontinuation of idelalisib. Blood. 2017;130(Suppl 1):4325.
1. Bird ST, Tian F, Flowers N, Przepiorka D, Wang R, Jung TH, et al. Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries. JAMA Oncol. 2020;6:248-54.